APX Ophthalmology Ltd was established in 2011 to develop and commercialize a novel iris retractor for cataract surgeries with small or constricted pupils. The company has developed two versions of their APX iris retractor - the APX 100 stainless steel version and the disposable APX 200 plastic version, which will be commercially available by the end of 2014. The company is seeking to raise $600,000 to fund operations until production and sales launch in 2015. Clinical trials with the APX retractor showed high effectiveness and ease of use compared to competitors. The company holds strong intellectual property on their iris retractor and plans to establish distribution partnerships to launch in the US and Europe in 2015.

1. September 2014
Tel Aviv - Israel

2. • APX Ophthalmology Ltd was established in 2011 by Prof. Ehud Assia, Elie
Eliachar, Nir Lilach and Mor Research Applications to develop and
commercialize a Novel Iris Retractor for Small and Constricted Pupils,
mainly for the cataract market.
• The Company has developed two versions of the APX device:
• APX 100 – a Stainless Steel device – Over 100 cases preformed
successfully in the USA & Israel. (Production halted - Replaced by APX200)
• APX 200 – a Plastic disposable set – To be Commercially available by the
end of 2014
• The Company seeks to raise 600,000$ - required to fund its expenses till the
production initiation and sales launch.
• First Revenues expected in 2015
2

3. • APX Ophthalmology
• Cataract Surgeries (According to WHO)
• The Market
• Small or Constricted Pupil (The Clinical Need)
• The APX Solution
• Competition Comparison
• Post Marketing Evaluation
• Intellectual Property
• Go to Market Strategy
• Potential Global Partners
• Licensee/Acquirer Value Proposition
• Deals in the Field
3

4. Ehud Assia, MD Eliahu Eliachar, BSc. Ilanit Frank Hakim
CMO& Co-Founder
Head of Ophthalmology dept.,
Meir Medical Center.
Professor of Ophthalmology-
Sackler Faculty of Medicine,
Tel-Aviv University.
Inventor of several
patents/applications and
Founder of Ophthalmological
ventures.
4
CEO, CTO & Co-Founder
CEO of Eliachar
Technologies Development
(Since 1996), one of the
leading product development
companies in Israel,
specializing in the Medical
Field.
Over 200 medical devices
developed in various fields.
Inventor and Co-Inventor of
over 80 filled patents.
Business Development
Director of Technology
Transfer in fields of Medical
Devices.
Has commercialized
numerous medical
technologies over the last 7
years.

5. 5
WHO estimations:
• around 20 million performed globally in 2010
• expected to reach 32 million by 2020.

6. 6
Total Expander
Market
% of Small
Pupil/IFIS
Cataract
Surgeries (M)*
Country
USA** 3.5 7% 245,000
Germany 0.8 5% 40,000
France 0.5 5% 25,000
India 5.2 3% 156,000
* source: WHO
**The US contribution towards the global cataract surgery devices market was 32% in 2010.

7.  Common in Eye Conditions Such as:
 Pseudoexfolialtion
 Intraocular inflammation (uveitis) or
surgery
 Secondary to local medications such as
Pilocarpine or systemica1 antagonist
(IFIS syndrome).
Operating Through Small Pupillary Aperture
Increases Complications
Small pupil
Normal pupil at phacoemulsification
Need: Easy and safe pupil expander
7

8. Practical, Clinically - Driven Features
A Safe Device that Doesn’t Slow Down
Surgery!
Features Benefits
Smooth insertion and removal
• Highly Safe
• Saves total procedure time
• Minimal learning curve
“Scissors Design” - Moveable tips
• “Contracted” at insertion
• “Expanded” at site
Horizontal external anchoring Does not Interfere with surgical maneuvers
External positioning and No intraocular manipulations required
maneuvering
The surgical field is not impeded by the
device
Two independent devices
2
3
4
8

9. 9
APX 100
Stainless Steel (2 Retractors + 1 Forceps)
APX 200
Plastic (2 Retractors + 2 Forceps)

10. APX 200 Malyugin Ring Iris Hooks
Iris Contact Points 4 8 4
External Anchoring Yes No Yes
Additional Incisions required 2 0 4
10
There are two families of Competitive devices:
1 – Various Rings, the Malyugin Ring being currently the most popular.
2 – Iris Hooks.
In addition to the Table below, we claim:
 Faster and Easier Positioning and Removal.
 External Positioning.
 No Intraocular Manipulations required.
 The Physician does not operate over the device.
 Less damage to the Iris due to a limited force spring expansion.

11. 11
Some comments and feedbacks from MDs:
Better than Malyugin for pupil dilation + easier to
remove + doesn’t interfere with
instruments/Phaco + doesn’t interfere with IOL
insertion through main incision
Novel, a true star raising technology for an
increasingly common surgical problem
Much easier insertion and removal compared to
Malyugin Ring or Iris Hooks
Excellent alternative for pupil dilation, in the
small pupil cases

12. 12
15 Cases, performed by 7 US KOLs
Ease of loading the device on forceps 4.5
Ease of insertion of the device into the
anterior chamber through a 19G incision
4.7
Ease of placing the hooks behind the iris 4.5
Effective dilation of the pupil 4.9
Ease of surgical maneuvers through the
dilated pupil
4.7
Stability of pupil dilation throughout surgery 4.9
Ease of removal of the device from the
anterior chamber
4.9
Ratings
Very Poor Poor Fair Good Very Good
1 2 3 4 5
How would you rate the device reliability? 4.9
How would you rate the device compared
to competitive alternatives?
4.7
How would you rate the performance of the
device for its intended use?
4.9
Overall satisfaction of the device? 4.8

13. 1. IRIS RETRACTOR, priority date 02/11/2009
[USA, EU, Australia, Canada, China, India, Israel, Japan, Korea,
Brazil, Russia]
2. IRIS RETRACTOR ASSEMBLIES, priority date 24/10/2011
3. IRIS RETRACTOR FORCEPS, priority date 19/04/2013
Strong Global IP Position
13

14. Distribution agreements - Product Launch in the US in 2015
Distribution agreements - Product Launch in Europe in 2015
Market Acceptance
14
M&A

15. 15

16. Establishing a real competition to the market leaders!
Value by:
• Increase revenues and market share
• Expand product portfolio
• Positioning as provider of Premium Products
• Positioning as “difficult cases” solution provider
16

17. ACQUISITION OF MICROSURGICAL TECHNOLOGY, INC.
by Halma (the owner of the Malyugin Ring):
The initial cash consideration is $57 million for the share
capital plus $2 million for cash retained in the business.
Contingent consideration of up to $43 million is payable if
earnings for the two years to March 2015 exceed pre-determined
targets.
Total Deal - $102M
*source: http://www.halma.com/about-halma/acquisitions/acquisitions-history/2012/acquisition-microsurgical-technology.
aspx
17

18. Thank you!
18
For more information, please contact
Ilanit Frank Hakim, ilanit@mor-research.com,
+972-52-3564329